Researcher
Shionogi & Co., Ltd., Japan
Disclosure(s): No financial relationships to disclose
Naoki Kohira, Ph.D.
Researcher
Shionogi & Co., Ltd.
1. Kohira N, Hackel MA, Oota M, Takemura M, Hu F, Mizuno H, Sahm DF, Yamano Y. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020. J Glob Antimicrob Resist. 2023 Mar;32:181-186.
2. Kohira N, Hackel MA, Ishioka Y, Kuroiwa M, Sahm DF, Sato T, Maki H, Yamano Y. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist. 2020 Sep;22:738-741.
3. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains. Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34.